肺癌药物市场按治疗类型、给药方法、治疗线、分期、处方状态、分销管道、癌症类型和最终用户划分－2025-2032 年全球预测

预计到 2032 年肺癌药物市场规模将成长至 598.9 亿美元，复合年增长率为 8.70%。

主要市场统计数据
基准年2024年	307亿美元
预计2025年	332.3亿美元
预测年份：2032年	598.9亿美元
复合年增长率（%）	8.70%

全面介绍影响肺癌治疗创新和交付的不断发展的科学、临床和卫生系统动态

由于持续的临床需求、快速的科学进步以及不断变化的监管和报销格局，肺癌治疗在肿瘤学中占据着举足轻重的地位。近年来，肺癌治疗已从千篇一律的细胞毒性疗法转变为利用标靶治疗和免疫调节的精准医疗模式。这种转变得益于对肿瘤分子特征的更深入研究、伴随诊断的广泛应用以及更精细的临床试验设计，这些设计加快了治疗方法检验并优化了患者选择。

此外，临床界越来越关注结合全身和局部干预的多药物联合治疗，旨在改善存活结果的同时维持生活品质。医疗保健系统和付款方正在适应长期治疗途径，这引发了关于价值、可负担性和公平获取的新问题。因此，产业、临床实践和政策层面的相关人员正在重新评估开发策略和商业模式，以确保科学前景与现实世界交付的一致性。在此背景下，仔细奖励临床证据、监管讯号、供应链韧性和相关人员，对于引导下一波投资和打入市场策略至关重要。

分子特征、联合免疫肿瘤学方法以及监管适应症的重大变化正在重新定义肺癌治疗策略

在科学突破、监管变革和治疗模式转变的共同推动下，肺癌治疗领域正经历一场变革性的转变。分子肿瘤学的进步已将可操作的标靶扩展到经典的驱动突变之外，而次世代定序仪和液态切片技术则使得早期准确地检测可操作的生物标誌物成为可能。同时，免疫肿瘤学已发展成为一种精细的组合策略，查核点抑制剂与标靶药物、抗体药物复合体或新型免疫调变器相结合，试图将持久应答者转化为更大规模的患者群体。

监管机构也不断调整，提供快速且适应性强的审批途径，奖励具有临床意义的改进，并促进与真实世界证据生成相关的有条件核准。付款人框架开始纳入基于结果的合约和特定适应症的定价，以管理长期成本风险。在研发方面，製药和生物技术公司正在深化与诊断开发商、委外研发机构和专业服务供应商的合作，以简化开发时间表并共同部署诊断和药物。因此，竞争差异化日益受到综合证据包、可扩展生产和灵活商业化策略的驱动，这些策略考虑到了异质性患者群体和多样化的医疗保健环境。

2025 年美国关税如何重塑肺癌治疗领域的供应链架构、製造决策和筹资策略的综合分析

2025年美国关税的累积效应正在为整个肺癌治疗价值链带来新的复杂性，影响製造成本、供应链设计和筹资策略。针对原材料、原料药和专用设备的关税调整，正在奖励申办方和製造外包重新评估其地理布局和供应商组合。为此，许多公司已启动双重采购策略并加强与供应商的伙伴关係，以降低集中化带来的脆弱性，并保持关键试剂和组件流通的连续性。

除了直接的成本影响外，关税还加速了围绕在岸生产和区域製造能力的讨论，以此作为缩短前置作业时间和降低跨境贸易波动风险的手段。此类策略措施通常需要大量的资本配置和监管协调，尤其是在迁移无菌注射剂和生物製药製造地时。因此，一些开发人员优先考虑流程整合和模组化製造技术，以实现灵活性，而无需完全迁移营运。

此外，关税也会对辅助服务产生连锁反应，例如诊断试剂的生产以及支援治疗管理和监测的医疗设备供应链。卫生系统正在调整其采购实践，以平衡短期预算压力和长期韧性，通常是透过与製造商协商长期合约或利用关键投入的策略性库存。总的来说，这些调整凸显了供应治疗方法透明度、情境规划以及与海关和贸易专家密切合作的重要性，以便在不断变化的关税环境中保持专案时间表和患者可及性。

治疗方式、治疗线、肿瘤类型、给药途径和分销管道的详细细分洞察决定了开发和获取

准确了解细分市场动态对于将开发和商业策略与临床现实和交付管道结合至关重要。在治疗方法分析治疗方法方法时，重要的是要考虑化疗、免疫疗法、放射线治疗和标靶治疗的不同发展路径和临床效用。化疗，包括烷化剂、铂类化合物、紫杉烷和拓朴异构酶抑制剂，在联合和序贯联合治疗中各占一席之地，并在特定方案中发挥重要作用。免疫疗法包括检查点抑制剂，例如 CTLA-4 抑制剂、PD-1 抑制剂和 PD-L1 抑制剂，具有不同的机制、给药方法和生物标记依赖性。放射放射线治疗仍然是一种重要的局部治疗方法，包括近距离放射治疗、体外放射治疗和立体定位放射治疗，每种治疗都有不同的适用性，取决于肿瘤位置和治疗目标。查核点标靶治疗越来越多地分子标靶进行分层，例如 ALK 抑制剂、BRAF 抑制剂、EGFR 抑制剂和 ROS1 抑制剂，这需要开发伴随诊断和抗药性管理策略。

治疗线细分揭示了临床开发和商业化的策略曲折点。辅助和新辅助适应症需要强大的转换终点和已证实的长期疗效，而一线、维持、二线、三线及以上适应症则需要在安全性、耐久性和序列相容性方面进行明确区分。早期候选药物的区分通常可以实现更广泛的应用，但也需要头对头和可操作的比较证据。在肺癌亚型中，非小细胞肺癌和小细胞肺癌有不同的生物学行为和治疗方法。 NSCLC 受益于丰富的标靶环境和对免疫疗法的反应性，而 SCLC 则需要注重全身性联合治疗和早期检测策略。

吸入、注射和口服等给药形式的考虑因素会影响患者的依从性、临床经济学和分销物流。口服製剂可以促进门诊病人的依从性并减少输液资源的压力，但需要监测依从性并考虑药物交互作用。吸入给药可提供所选治疗方法的局部暴露，但取决于设备相容性和付款人的接受度。注射剂，尤其是生技药品和 ADC，需要输液基础设施和低温运输物流。最后，医院药局、线上药局、零售药局和专科诊所之间的分销管道细分会影响取得途径和报销谈判点。每个管道都有独特的合约动态和对患者援助计划的影响，而专科诊所通常充当复杂治疗管理和监测的中心。这些细分结合起来，为临床项目优先排序、供应策略和商业性参与计划提供信息，以符合临床效用和医疗服务提供实际情况。

亚太、欧洲和中东地区的关键区域动态将影响治疗可近性、报销和分销策略

区域动态对监管时间表、报销框架和商业性实施策略有重大影响。在美洲，监管机构和付款人高度重视比较有效性和基于价值的安排，公立和私立医疗体系的采用模式各不相同。该地区通常在新型标靶治疗和免疫疗法的快速采用方面处于领先地位，但面临着付款人主导的药物利用管理和价格谈判的压力，需要强有力的健康经济证据和患者支持计划。

欧洲、中东和非洲地区的监管途径和报销方式差异巨大。西方市场通常需要全面的卫生技术评估和真实世界证据，而该地区新兴市场的可负担性和可近性项目可能更具优先地位。监管协调工作和跨境临床合作对于实现药物开发规模化和核准后证据生成变得越来越重要。中东和非洲地区既充满机会，也面临复杂性，其基础建设多样、疾病负担报告差异化，采购模式也各有不同，需要采取灵活的市场进入策略。

亚太地区呈现出多元化的格局，其快速应用受到区域监管改革、国内製造能力和国家癌症控制重点的推动。该地区一些国家正在透过与真实世界证据相关的条件性途径加速标靶治疗药物和免疫疗法的核准，而其他国家则保持严格的本地临床要求。此外，在扩大基因组检测和分散式医疗服务方面也取得了进展，重塑了患者识别和治疗的进程。总而言之，这些区域差异凸显了製定量身定制的证据策略、弹性价格设定以及应对监管和基础设施多样性的供应链设计的需求。

策略竞争概述强调了整合的产品组合、创新的生物技术产品线和合作伙伴生态系统，加速了肺癌治疗的进展

肺癌治疗领域的竞争格局特征是大型製药企业、致力于推进新治疗方法的生物技术公司以及支持快速开发和商业化的专业服务供应商的混合。市场领导者往往透过整合后期资产、深厚的研发管线和成熟的商业基础设施，从而实现差异化竞争。这些公司通常利用其全球监管经验和付款人参与能力来加速产品上市，并将自己定位为治疗替代药物。

规模较小的生物技术公司和大学衍生公司正在为创新做出重大贡献，尤其是在双特异性抗体、抗体药物复合体和细胞疗法等新型治疗方法。这些公司通常会与主要赞助商建立策略联盟或选择性共同开发契约，以确保开发和商业规模。同时，诊断开发商是伴随检测和生物标记主导的临床策略的关键合作伙伴。竞争对手的成功越来越取决于他们能否提供整合的证据、建立灵活的商业模式，并在不同的医疗保健体系中展现其实际效用。

为开发商和商业团队提供可行的策略要务，以协调生物标誌物主导的开发、供应弹性和付款人就绪证据的生成

产业领导者应优先考虑一系列可行的倡议，以应对临床复杂性、供应链中断和付款人需求。首先，将开发项目与强大的生物标记策略和伴随诊断相结合，可以改善患者选择，并强化对付款人和临床医生的价值提案。早期投资于转化研究和自适应试验设计可以缩短开发週期，并与标准治疗药物进行更清晰的区分。其次，透过多元化采购、区域製造伙伴关係和模组化生产技术来建立供应链弹性，有助于满足交货期限，同时降低与关税和中断相关的风险。

第三，商业团队应设计证据产生计划，包括真实世界数据收集、健康经济模型和基于结果的合约选项，以解决付款人对长期价值的担忧。关键意见领袖和多学科护理中心的早期参与可以促进指南的纳入和适当的采用。第四，优化患者支援和依从性计划（尤其是口服和门诊药物）将促进保留和疗效，并需要与数位工具和专业药房网路整合。最后，公司应考虑弹性价格设定和可及性策略，以反映区域负担能力的限制，并透过利用分级合约、同情用药伙伴关係以及与公共和非营利利益相关人员的策略伙伴关係来促进公平可及性。总之，这些行动为将科学进步转化为永续的临床和商业性影响提供了切实可行的蓝图。

一种透明的调查方法，结合文献综述、专家意见和跨学科证据综合，以支持可行的结论和决策

本分析所依据的调查方法结合了系统性的文献回顾、专家访谈和跨部门证据三角检验，以确保获得可靠且可操作的见解。本研究审查了同行评审的临床数据、监管指南文件和公共卫生建议，以支持临床和监管解释。此外，来自临床医生、药物经济学家、供应链专家和诊断开发人员的主要定性意见，为实施、病患路径和报销动态提供了实用见解。

调查方法强调整合临床前机制理解、临床试验结果与真实世界临床实务模式的证据。分析技术包括治疗类别的比较评估、供应链紧急情境规划以及商业模式的定性评估。透过与领域专家的研讨会检验假设，并注意交叉引用已发表的监管资讯和政策解读。限制包括快速发展的临床证据和政策环境；本调查方法透过鼓励定期更新和逐步深化与主要监管和临床拐点相关的研究来解决这些限制。

科学创新、营运弹性和付款人一致的证据策略的相互作用对于维持患者影响至关重要

总而言之，肺癌治疗正处于一个十字路口，科学发展势头必须与营运灵活性和相关人员一致的价值展示相匹配。分子标靶治疗、免疫肿瘤学和诊断技术的进步拓展了治疗的可能性，但成功的商业化取决于将这些进步转化为可及且永续的治疗途径。供应链中断和贸易政策的转变凸显了韧性规划的重要性，而付款方的期望也越来越要求全面的现实世界证据和以结果为导向的合约。

展望未来，将生物标记主导的研发与灵活的生产、区域可及性策略以及以付款人为导向的证据计划相结合的相关人员，将最有能力将临床创新转化为对患者有意义的影响。在临床、监管、商业和供应链领域保持密切合作，将有助于各机构应对复杂情况，并加速将有前景的治疗方法转化为改善肺癌患者预后的标准治疗方案。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 透过探索 PD-1 和 PD-L1 以外的新查核点靶点，扩大肺癌免疫治疗适应症
• 人工智慧驱动的放射组学和基因组学整合，用于肺癌治疗中的预测性生物标记识别
• 一种新型双特异性抗体方法针对两种致癌途径治疗非小细胞肺癌（NSCLC）
• 引入液态生物检体检测，用于个人化监测肺癌治疗反应
• 开发新型 KRAS G12C 抑制剂和联合治疗以克服非小细胞肺癌 (NSCLC) 的抗药性
• 基于吸入奈米载体的药物输送系统在标靶治疗中的进展
• EGFR外显子20插入突变治疗及NSCLC临床试验结果日益重要
• 采用真实世界证据框架加速肺癌治疗途径的监管核准
• TCR-T细胞和NK细胞在晚期肺癌治疗的应用
• 专注于克服标靶治疗和免疫治疗中的抗药性机制

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章肺癌药物市场依治疗类型

• 化疗
  • 烷化剂
  • 铂金基地
  • 紫杉烷类
  • 拓朴异构酶抑制剂
• 免疫疗法
  • CTLA-4抑制剂
  • PD-1抑制剂
  • PD-L1抑制剂
• 放射治疗
  • 近距离放射治疗
  • 体外照射
  • 立体定位放射治疗
• 支持性护理
  • 止吐药
  • 骨骼改质剂
  • 造血生长因子
• 外科手术
• 标靶治疗
  • 间变性淋巴瘤激酶（ALK）抑制剂
  • BRAF抑制剂
  • EGFR抑制剂

9. 按给药方式分類的肺癌药物市场

• 吸入
• 注射
• 口服

10. 肺癌药物市场治疗线

• 一线
• 第二行
• 三线及以后

第11章肺癌药物市场（依疾病阶段）

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第十二章肺癌药物市场（依处方笺状况）

• 品牌
• 非专利的

第十三章肺癌药物市场（按分销管道）

• 线下零售
• 网路零售

第十四章肺癌治疗药物市场（依癌症类型）

• 非小细胞肺癌（NSCLC）
  • 腺癌
  • 大细胞癌
  • 鳞状细胞癌
• 小细胞肺癌（SCLC）

第十五章肺癌药物市场（依最终用户）

• 门诊输液中心
• 癌症中心
• 居家照护环境
• 医院

第十六章肺癌药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十七章肺癌药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十八章 肺癌药物市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十九章 竞争态势

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited

The Lung Cancer Therapeutics Market is projected to grow by USD 59.89 billion at a CAGR of 8.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 30.70 billion
Estimated Year [2025]	USD 33.23 billion
Forecast Year [2032]	USD 59.89 billion
CAGR (%)	8.70%

Comprehensive introduction to the evolving scientific, clinical, and health system dynamics shaping lung cancer therapeutic innovation and delivery

Lung cancer therapeutics occupy a pivotal position within oncology due to persistent clinical need, rapid scientific advances, and evolving regulatory and reimbursement landscapes. Recent years have seen a shift from one-size-fits-all cytotoxic approaches toward precision medicine paradigms that harness targeted therapies and immune modulation. This transformation is underpinned by deeper molecular characterization of tumors, broader adoption of companion diagnostics, and more sophisticated clinical trial designs that accelerate therapeutic validation while refining patient selection.

Moreover, the clinical community is increasingly focused on integrating multimodal regimens that combine systemic agents with localized interventions, aiming to improve survival outcomes while preserving quality of life. Health systems and payers are adapting to long-term treatment pathways that raise new questions about value, affordability, and equitable access. Consequently, stakeholders across industry, clinical practice, and policy are re-evaluating development strategies and commercial models to align scientific promise with real-world delivery. In this context, careful synthesis of clinical evidence, regulatory signals, supply chain resilience, and stakeholder incentives becomes essential for guiding next-wave investments and market entry strategies.

High-impact shifts in molecular characterization, combination immuno-oncology approaches, and regulatory adaptation that are redefining therapeutic strategies for lung cancer

The landscape of lung cancer therapeutics is experiencing transformative shifts driven by convergence of scientific breakthroughs, regulatory evolution, and changing care paradigms. Advances in molecular oncology have expanded actionable targets beyond classical driver mutations, while next-generation sequencing and liquid biopsy technologies have enabled earlier and more accurate detection of actionable biomarkers. At the same time, immuno-oncology has matured into nuanced combination strategies that seek to convert durable responders into a larger patient cohort by pairing checkpoint inhibitors with targeted agents, antibody-drug conjugates, or novel immune modulators.

Regulatory bodies are also adapting, offering accelerated and adaptive pathways that reward clinically meaningful improvements and facilitate conditional approvals tied to real-world evidence generation. Payer frameworks are beginning to incorporate outcomes-based contracting and indication-specific pricing to manage long-term cost exposure. Operationally, pharmaceutical and biotech companies are forging deeper collaborations with diagnostic developers, contract research organizations, and specialized service providers to streamline development timelines and ensure diagnostic-drug co-deployment. As a result, competitive differentiation increasingly depends on integrated evidence packages, scalable manufacturing, and flexible commercialization strategies that account for heterogeneous patient populations and diverse care settings.

Integrated analysis of how 2025 United States tariff measures are reshaping supply chain architectures, manufacturing decisions, and procurement strategies across lung cancer therapeutics

The cumulative effects of tariff actions originating in the United States in 2025 have introduced new layers of complexity across the lung cancer therapeutics value chain, influencing production costs, supply chain design, and sourcing strategies. Tariff adjustments that apply to raw materials, active pharmaceutical ingredients, and specialized equipment have created incentives for sponsors and contract manufacturing partners to reassess geographic footprints and supplier portfolios. In response, many organizations have initiated dual-sourcing strategies and closer supplier partnerships to mitigate single-point vulnerabilities and preserve continuity of critical reagent and component flows.

Beyond direct cost implications, tariffs have accelerated conversations around onshoring and regional manufacturing capacity as a means to shorten lead times and reduce exposure to cross-border trade volatility. Such strategic moves typically require significant capital allocation and regulatory alignment, particularly when relocating sterile injectable or biologic drug production. Consequently, some developers have prioritized process intensification and modular manufacturing technologies to achieve flexibility without fully relocating operations.

Additionally, tariffs have ripple effects on ancillary services, including diagnostic test production and medical device supply chains that support therapeutic administration and monitoring. Health systems are adapting procurement practices to balance near-term budgetary pressures against long-term resilience, often negotiating longer-term contracts with manufacturers or leveraging strategic inventories for critical inputs. In aggregate, these adjustments emphasize the importance of supply chain transparency, scenario planning, and close engagement with customs and trade specialists to maintain program timelines and patient access in a shifting tariff environment.

In-depth segmentation insights across therapeutic modalities, lines of care, tumor types, administration routes, and distribution channels shaping development and access

A nuanced understanding of segment-level dynamics is essential for aligning development and commercial strategies with clinical realities and delivery channels. When therapies are analyzed by therapy type, it is important to consider the distinct developmental pathways and clinical utility of chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy retains a foundational role in certain regimens, with alkylating agents, platinum-based compounds, taxanes, and topoisomerase inhibitors each occupying defined niches in combination and sequential approaches. Immunotherapy encompasses checkpoint blockade modalities such as CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, which vary in mechanism, dosing paradigms, and biomarker dependencies. Radiation therapy remains a critical local modality and includes brachytherapy, external beam radiation, and stereotactic body radiation, each offering differential applicability based on tumor location and intent of care. Targeted therapy is increasingly stratified by molecular targets, including ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, which demand companion diagnostic alignment and resistance-management strategies.

Line-of-therapy segmentation reveals strategic inflection points for clinical development and commercialization. Adjuvant and neoadjuvant settings require robust translational endpoints and longer-term outcome demonstration, while first-line, maintenance, second-line, and third-line-and-beyond indications demand clear differentiation on safety, durability, and sequencing compatibility. Differentiating a candidate in early lines often unlocks broader adoption but also requires head-to-head or pragmatic comparative evidence. When classifying by type of lung cancer, non-small cell lung cancer and small cell lung cancer present divergent biological behaviors and therapeutic modalities; NSCLC benefits from a rich targetable landscape and immunotherapy responsiveness, whereas SCLC requires intensified focus on systemic combinations and early detection strategies.

Mode-of-administration considerations-whether inhalation, injectable, or oral-shape patient adherence, site-of-care economics, and distribution logistics. Oral agents facilitate outpatient continuity and can reduce infusion resource burden, but raise adherence monitoring and drug-drug interaction considerations. Inhalation delivery offers localized exposure for select therapeutic modalities but depends on device compatibility and payer acceptance. Injectable therapeutics, particularly biologics and ADCs, demand infusion infrastructure and cold-chain logistics. Finally, distribution channel segmentation spanning hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics influences access pathways and reimbursement negotiation points. Each channel has unique contracting dynamics and patient support program implications, with specialty clinics often central to complex therapy administration and monitoring. Taken together, these segmentation lenses inform prioritization of clinical programs, supply strategies, and commercial engagement plans that align with clinical utility and care delivery realities.

Critical regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory access, reimbursement, and distribution strategies for therapeutics

Regional dynamics exert strong influence on regulatory timelines, reimbursement frameworks, and commercial execution strategies. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and value-based arrangements, with heterogeneous adoption patterns across public and private systems. This region often leads in rapid adoption of novel targeted agents and immunotherapies but faces pressure from payer-driven utilization management and pricing negotiations that necessitate robust health economic evidence and patient support programs.

Across Europe, the Middle East, and Africa, regulatory pathways and reimbursement approaches vary widely. Western European markets typically demand comprehensive health technology assessments and real-world evidence, while emerging markets in the region may prioritize affordability and access programs. Regulatory harmonization efforts and cross-border clinical collaborations are increasingly important for achieving scale in drug development and post-approval evidence generation. The Middle East and Africa present both opportunity and complexity due to variable infrastructure, heterogeneous disease burden reporting, and different procurement models that require adaptive market-entry tactics.

The Asia-Pacific region represents a diverse landscape where rapid adoption can hinge on local regulatory reforms, domestic manufacturing capacity, and national cancer control priorities. Several countries in the region are accelerating approvals for targeted therapies and immunotherapies through conditional pathways tied to real-world evidence, while others maintain stringent local clinical requirements. Additionally, evolving initiatives to expand genomic testing and decentralized care delivery are reshaping patient identification and treatment uptake. Collectively, these regional nuances highlight the need for geographically tailored evidence strategies, flexible pricing arrangements, and supply-chain designs that accommodate regulatory and infrastructural diversity.

Strategic competitive overview emphasizing integrated portfolios, biotech innovation pipelines, and partner ecosystems that accelerate lung cancer therapeutic advancement

The competitive landscape in lung cancer therapeutics is characterized by a blend of large pharmaceutical companies, biotechs advancing novel modalities, and specialized service providers that enable rapid development and commercialization. Market leaders tend to differentiate through integrated portfolios that combine late-stage assets, pipeline depth, and established commercial infrastructure. These organizations often leverage global regulatory experience and payer engagement capabilities to accelerate launches and secure place-in-therapy positions.

Smaller biotechs and academic spinouts contribute disproportionate innovation, particularly in emerging modalities such as bispecific antibodies, antibody-drug conjugates, and cell-based therapies. These entities frequently pursue strategic partnerships or selective co-development agreements with larger sponsors to access development and commercial scale. Contract research and manufacturing partners play an instrumental role in enabling flexible development timelines and managing biologics complexity, while diagnostics developers are critical collaborators for companion assays and biomarker-driven clinical strategies. Across the competitive set, success increasingly depends on integrated evidence generation, adaptable commercial models, and the ability to demonstrate real-world benefit in diverse health system contexts.

Actionable strategic imperatives for developers and commercial teams to align biomarker-driven development, supply resilience, and payer-ready evidence generation

Industry leaders should prioritize a set of actionable initiatives to navigate clinical complexity, supply-chain disruption, and payer demands. First, aligning development programs with robust biomarker strategies and companion diagnostics will improve patient selection and strengthen value propositions for payers and clinicians. Investing early in translational research and adaptive trial designs can shorten development cycles and create clearer differentiation against standard-of-care comparators. Secondly, building supply-chain resilience through diversified sourcing, regional manufacturing partnerships, and modular production technologies will mitigate tariff- and disruption-related risks while preserving delivery timelines.

Third, commercial teams should design evidence-generation plans that include real-world data collection, health economic modelling, and outcomes-based contracting options to address payer concerns about long-term value. Engaging key opinion leaders and multidisciplinary treatment centers early can facilitate guideline inclusion and appropriate uptake. Fourth, optimizing patient support and adherence programs-particularly for oral and outpatient-administered therapeutics-will drive persistence and outcomes, requiring integration with digital tools and specialty pharmacy networks. Finally, companies should consider flexible pricing and access strategies that reflect regional affordability constraints and promote equitable access, leveraging tiered contracting, compassionate use frameworks, and strategic partnerships with public and non-profit stakeholders. Taken together, these actions create a pragmatic road map for translating scientific advances into sustainable clinical and commercial impact.

Transparent research methodology combining literature review, expert input, and cross-functional evidence integration to support actionable conclusions and decision-making

The research approach underpinning this analysis combines systematic literature synthesis, expert interviews, and cross-functional evidence triangulation to ensure robust and actionable insights. Peer-reviewed clinical data, regulatory guidance documents, and public health advisories were reviewed to anchor clinical and regulatory interpretations. In addition, primary qualitative inputs from clinicians, pharmacoeconomists, supply-chain specialists, and diagnostic developers informed practical considerations around implementation, patient pathways, and reimbursement dynamics.

Methodologically, the study emphasizes evidence integration across preclinical mechanistic understanding, clinical trial outcomes, and real-world practice patterns. Analytical techniques included comparative therapeutic class assessment, scenario planning for supply-chain contingencies, and qualitative valuation of commercial models. Care was taken to validate assumptions through subject matter expert workshops and to cross-check policy interpretations with publicly available regulatory communications. Limitations include the rapidly evolving nature of clinical evidence and policy environments, which the methodology addresses by recommending periodic updates and staged deep dives tied to major regulatory or clinical inflection points.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and payer-aligned evidence strategies to achieve durable patient impact

In conclusion, lung cancer therapeutics stand at a juncture where scientific momentum must be matched by operational dexterity and stakeholder-aligned value demonstration. Advances in molecular targeting, immuno-oncology, and diagnostics have expanded therapeutic possibilities, yet commercialization success will hinge on the ability to translate those advances into accessible, sustainable care pathways. Supply-chain disruptions and trade policy shifts have underscored the importance of resilience planning, while payer expectations increasingly demand comprehensive real-world evidence and outcomes-focused contracting.

Looking forward, stakeholders who integrate biomarker-driven development with flexible manufacturing, region-specific access strategies, and payer-oriented evidence plans will be best positioned to convert clinical innovation into meaningful patient impact. By maintaining close collaboration across clinical, regulatory, commercial, and supply-chain disciplines, organizations can navigate complexity and accelerate the translation of promising therapies into standard-of-care options that improve outcomes for patients with lung cancer.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of immunotherapy indications exploring novel checkpoint targets beyond PD-1 and PD-L1 in lung cancer
• 5.2. Integration of AI-driven radiomics and genomics for predictive biomarker identification in lung cancer therapy
• 5.3. Emerging bispecific antibody approaches targeting two oncogenic pathways in NSCLC treatment
• 5.4. Incorporation of liquid biopsy assays for personalized monitoring of therapeutic response in lung cancer
• 5.5. Development of novel KRAS G12C inhibitors and combination regimens to overcome resistance in NSCLC
• 5.6. Advancements in inhalable nanocarrier-based drug delivery systems for targeted lung cancer therapy
• 5.7. Growing emphasis on EGFR exon 20 insertion mutation therapies and clinical trial outcomes in NSCLC
• 5.8. Adoption of real-world evidence frameworks to accelerate regulatory approvals in lung cancer treatment pathways
• 5.9. Emergence of cellular therapies including TCR-T and NK cell approaches for advanced lung cancer management
• 5.10. Focus on overcoming resistance mechanisms in targeted and immunotherapy treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Therapeutics Market, by Therapy Type

• 8.1. Chemotherapy
  • 8.1.1. Alkylating Agents
  • 8.1.2. Platinum-Based
  • 8.1.3. Taxanes
  • 8.1.4. Topoisomerase Inhibitors
• 8.2. Immunotherapy
  • 8.2.1. CTLA-4 Inhibitors
  • 8.2.2. PD-1 Inhibitors
  • 8.2.3. PD-L1 Inhibitors
• 8.3. Radiation Therapy
  • 8.3.1. Brachytherapy
  • 8.3.2. External Beam Radiation
  • 8.3.3. Stereotactic Body Radiation
• 8.4. Supportive Care
  • 8.4.1. Antiemetics
  • 8.4.2. Bone-Modifying Agents
  • 8.4.3. Hematopoietic Growth Factors
• 8.5. Surgery
• 8.6. Targeted Therapy
  • 8.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
  • 8.6.2. BRAF Inhibitors
  • 8.6.3. EGFR Inhibitors

9. Lung Cancer Therapeutics Market, by Mode Of Administration

• 9.1. Inhalation
• 9.2. Injectable
• 9.3. Oral

10. Lung Cancer Therapeutics Market, by Line Of Therapy

• 10.1. First-Line
• 10.2. Second-Line
• 10.3. Third-Line & Beyond

11. Lung Cancer Therapeutics Market, by Disease Stage

• 11.1. Stage I
• 11.2. Stage II
• 11.3. Stage III
• 11.4. Stage IV

12. Lung Cancer Therapeutics Market, by Prescription Status

• 12.1. Branded
• 12.2. Generic

13. Lung Cancer Therapeutics Market, by Distribution Channel

• 13.1. Offline Retail
• 13.2. Online Retail

14. Lung Cancer Therapeutics Market, by Cancer Type

• 14.1. Non-Small Cell Lung Cancer (NSCLC)
  • 14.1.1. Adenocarcinoma
  • 14.1.2. Large Cell Carcinoma
  • 14.1.3. Squamous Cell Carcinoma
• 14.2. Small Cell Lung Cancer (SCLC)

15. Lung Cancer Therapeutics Market, by End User

• 15.1. Ambulatory Infusion Centers
• 15.2. Cancer Centers
• 15.3. Homecare Settings
• 15.4. Hospitals

16. Lung Cancer Therapeutics Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Lung Cancer Therapeutics Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Lung Cancer Therapeutics Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Share Analysis, 2024
• 19.2. FPNV Positioning Matrix, 2024
• 19.3. Competitive Analysis
  • 19.3.1. AbbVie Inc.
  • 19.3.2. Amgen Inc.
  • 19.3.3. Astellas Pharma Inc.
  • 19.3.4. AstraZeneca PLC
  • 19.3.5. Bayer AG
  • 19.3.6. Boehringer Ingelheim International GmbH
  • 19.3.7. Johnson & Johnson Services, Inc.
  • 19.3.8. Merck & Co., Inc.
  • 19.3.9. Novartis AG
  • 19.3.10. Pfizer Inc.
  • 19.3.11. Sanofi S.A
  • 19.3.12. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 35. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 36. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 292. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 298. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILL